FDA Approves Self-Collection Kits for Cervical Cancer Screening

New self-collection method aims to increase accessibility and early detection, potentially reducing cervical cancer rates.

Women can now collect their own samples for HPV testing in clinical settings, with potential for at-home use in the future.
The FDA's approval covers self-collection kits from Roche and BD, enhancing screening options for underserved communities.
HPV is the primary cause of cervical cancer, which affects over 11,000 women annually in the U.S.
Self-collection is expected to remove barriers related to discomfort and access, encouraging more women to get screened.
Studies show self-collected samples are as accurate as those collected by clinicians, paving the way for broader adoption.